Content about Pioglitazone

February 19, 2013
FDA approves Aurobindo diabetes drug

The Food and Drug Administration has approved a generic diabetes drug made by Aurobindo Pharma, the drug maker said.

February 8, 2013
FDA approves generic diabetes drug

The Food and Drug Administration has approved a generic diabetes drug made by Macleods Pharma, according to agency records.

January 28, 2013
FDA approves three new drugs for Type 2 diabetes

The Food and Drug Administration has approved three new drugs for Type 2 diabetes made by Takeda, the agency said.

November 15, 2012
NewsBytes — Chain Pharmacy, 11/19/12

The Food and Drug Administration has approved a generic drug for leukemia made by a subsidiary of Par Pharmaceutical Cos.


October 29, 2012
Watson launches generic version of Actos

The Food and Drug Administration has approved a Type 2 diabetes drug made by Watson Pharmaceuticals, the company said, following a federal court's order for the agency to approve the drug.

October 24, 2012
Mylan hopes to stop Watson launch of diabetes drug

Mylan is challenging a federal court decision ordering the Food and Drug Administration to allow Watson Pharmaceuticals to launch a generic diabetes drug, Mylan said.

October 23, 2012
Federal court orders FDA to allow Watson diabetes drug launch

A federal court has ordered the Food and Drug Administration to approve a generic diabetes drug made by Watson Pharmaceuticals, the drug maker said.

August 27, 2012
FDA approves generic version of Actos

The Food and Drug Administration has approved the first generic version of a diabetes drug made by Takeda, the agency said Friday.

August 17, 2012
Ranbaxy launches authorized generic diabetes drug

Ranbaxy Labs has launched an authorized generic version of a diabetes drug made by Takeda Pharmaceutical, Ranbaxy said Friday.

August 17, 2012
Teva launches authorized generic Actos

Teva Pharmaceutical Industries announced the launch of an authorized generic of a Type 2 diabetes drug.

August 15, 2012
Watson sues FDA over generic Actos

Watson Pharmaceuticals is suing the Food and Drug Administration, alleging that an agency decision would improperly delay its release of a generic drug for diabetes, the company said Wednesday.

July 30, 2012
Takeda resubmits diabetes drug applications

Drug maker Takeda Pharmaceutical has resubmitted regulatory approval applications for two drugs designed to treat diabetes, the company said.

July 23, 2012
Study: Long-term use of linagliptin among Type 2 diabetics is effective

Extended use of the oral DPP-4 inhibitor linagliptin to lower blood-glucose levels by Type 2 diabetes patients is effective, according to a new study.

April 26, 2012
FDA declines to approve Takeda diabetes drug

The Food and Drug Administration declined to approve a drug made by Takeda Pharmaceutical, the drug maker said.

January 9, 2012
Mylan seeks approval for generic diabetes drug

Generic drug maker Mylan is challenging the patent on a drug used to treat diabetes, the company said Monday.

September 16, 2011
BI, Lilly drug reduces blood sugar over long term

A drug made by Boehringer Ingelheim and Eli Lilly showed "meaningful and durable" reductions in blood sugar in adults with Type 2 diabetes, according to results of a late-stage clinical trial presented Friday at a conference in Europe.

September 12, 2011
Studies: Bydureon shows improvements in cardiovascular health

Patients treated with a long-acting drug for Type 2 diabetes experienced a reduction in cardiovascular health risk factors, according to results of a study presented at the European Association for the Study of Diabetes' annual meeting.

July 26, 2011
Takeda resubmits new drug applications for Type 2 diabetes treatments

Japanese drug maker Takeda Pharmaceutical is reapplying for approval of two drugs to treat Type 2 diabetes after the Food and Drug Administration turned down its last applications, the company said.

July 14, 2011
Takeda pulls two diabetes drugs off French market

OSAKA, Japan — Two diabetes drugs made by Takeda Pharmaceutical Co. have been pulled from the market in France due to evidence that their use may increase the risk of bladder cancer, Takeda said.

Takeda said its French subsidiary, Laboratoires Takeda, would withdraw Actos (pioglitazone) and Competact (pioglitazone and metformin). In addition, Takeda said it was cooperating with the European Medicines Agency in a pan-European of pioglitazone. Competact is marketed in the United States under the brand name Actoplus Met.

June 20, 2011
Q&A: A new drug for Type 2 diabetes — Wa'el Hashad, Boehringer Ingelheim

Last month, the Food and Drug Administration approved Tradjenta (linagliptin), an oral Type 2 diabetes drug made by German drug maker Boehringer Ingelheim and Indianapolis-based Eli Lilly. The drug belongs to the class known as dipeptidyl peptidase-4 inhibitors, which also includes Merck’s Januvia (sitagliptin). With diabetes affecting some 26 million Americans and growing rapidly, Drug Store News spoke with Wa’el Hashad, BI’s VP cardiovascular and metabolic disorders marketing, about what the approval of Tradjenta means for the diabetes market.


June 17, 2011
FDA updates ongoing safety review of Actos

The Food and Drug Administration on Thursday informed the public that continued use of a Type 2 diabetes treatment made by Takeda Pharmaceuticals for more than one year may be associated with an increased risk of bladder cancer.

March 25, 2011
Actos cuts Type 2 diabetes risk among majority of patients, study finds

A drug for Type 2 diabetes made by Takeda Pharmaceutical taken in the morning prevented the disease from developing in nearly three-quarters of patients who were at risk, according to a new study in the New England Journal of Medicine.

March 18, 2011
Journal notes heart-related risks posed by Avandia

With respect to the Type 2 diabetes drug Avandia, British drug maker GlaxoSmithKline has another medical study to worry about.

February 2, 2011
Decision Resources: Bydureon could promote weight loss among patients

Eli Lilly’s and Amylin Pharmaceuticals’ Type 2 diabetes drug, Bydureon, appears to work better at promoting weight loss than drugs made by Takeda and Merck, but it could face a challenger of its own.

January 17, 2011
Takeda, Zinfandel form partnership

Japanese drug maker Takeda Pharmaceutical has signed an agreement with Durham, N.C.-based Zinfandel Pharmaceuticals to develop a test for assessing Alzheimer’s disease risk in adults, the two companies said.

© 2013 Drug Store News. All Rights Reserved.